Birchview Capital, LP 2seventy Bio, Inc. Transaction History
Birchview Capital, LP
- $108 Million
- Q3 2024
A detailed history of Birchview Capital, LP transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 15,833 shares of TSVT stock, worth $40,215. This represents 0.07% of its overall portfolio holdings.
Number of Shares
15,833
Previous 17,833
11.22%
Holding current value
$40,215
Previous $68,000
8.82%
% of portfolio
0.07%
Previous 0.07%
Shares
6 transactions
Others Institutions Holding TSVT
# of Institutions
128Shares Held
45.6MCall Options Held
122KPut Options Held
19.8K-
Kynam Capital Management, LP Princeton, NJ5.95MShares$15.1 Million2.31% of portfolio
-
Goldman Sachs Group Inc New York, NY4.22MShares$10.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.77MShares$9.58 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.66MShares$9.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.89MShares$7.35 Million0.0% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $96.2M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...